Skip to content

Study · Observational study · n = 50 · 2010

4 results

Adherence and persistence in patients with severe osteoporosis treated with teriparatide.

Ziller V, Zimmermann SP, Kalder M, Ziller M, Seker-Pektas B, Hellmeyer L, Hadji P

Current medical research and opinion1 Mar 2010Cited by 30 (Europe PMC)

PMID20078188 (opens in a new tab)DOI10.1185/03007990903538409 (opens in a new tab)PepBankPUB-20078188
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyOther

    Among women with severe postmenopausal osteoporosis treated with teriparatide, 80% were adherent after 12 months.

    In plain wordsAmong women with severe osteoporosis, 80% adhered to teriparatide treatment after 12 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableTreatment adherence
    Study

    n = 50

    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Adherence
    80%
    12 months
    Non-adherence
    20%
    12 months

    Source sentences

    Summary
    After 12 months, 80% of the patients treated with TPTD were adherent, while 20% were non-adherent.
    5 context sentences
    Summary · context
    A sample of 50 women with severe postmenopausal osteoporosis treated with TPTD in accordance to the German osteoporosis guidelines was included.
    Summary · context
    Patient self report was assessed using a validated questionnaire.
    Summary · context
    In addition medication possession ratio (MPR) was calculated by counting prescription refills, and therefore all physicians who were treating the patients for any disease were contacted.
    Summary · context
    Patients were classified adherent at 12 months of therapy if self-reported adherence and an MPR of > or =80% were achieved.
    Summary · context
    Persistence was calculated in months and analysed with a Kaplan-Meier estimate.
  2. 02HumanObservational studyOther

    Among women with severe postmenopausal osteoporosis treated with teriparatide, 79% remained persistent after 12 months.

    In plain wordsAmong women with severe osteoporosis, 79% continued teriparatide treatment after 12 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableTreatment persistence
    Study

    n = 50

    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Persistence
    79%
    12 months

    Source sentences

    Summary
    Furthermore 79% of patients were persistent after 12 months.
    5 context sentences
    Summary · context
    A sample of 50 women with severe postmenopausal osteoporosis treated with TPTD in accordance to the German osteoporosis guidelines was included.
    Summary · context
    Patient self report was assessed using a validated questionnaire.
    Summary · context
    In addition medication possession ratio (MPR) was calculated by counting prescription refills, and therefore all physicians who were treating the patients for any disease were contacted.
    Summary · context
    Patients were classified adherent at 12 months of therapy if self-reported adherence and an MPR of > or =80% were achieved.
    Summary · context
    Persistence was calculated in months and analysed with a Kaplan-Meier estimate.

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In women treated with teriparatide, self-reported medication tolerability was significantly linked to treatment adherence.

    In plain wordsIn women treated with teriparatide, reported tolerability was linked to treatment adherence.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Direction not reportedTolerability association with adherence
    Study

    n = 50

    Outcome group
    Treatment adherence and retention · Whole body

    Source sentences

    Summary
    A significant correlation with treatment adherence was found for self-reported medication tolerability (p < 0.001).
    5 context sentences
    Summary · context
    A sample of 50 women with severe postmenopausal osteoporosis treated with TPTD in accordance to the German osteoporosis guidelines was included.
    Summary · context
    Patient self report was assessed using a validated questionnaire.
    Summary · context
    In addition medication possession ratio (MPR) was calculated by counting prescription refills, and therefore all physicians who were treating the patients for any disease were contacted.
    Summary · context
    Patients were classified adherent at 12 months of therapy if self-reported adherence and an MPR of > or =80% were achieved.
    Summary · context
    Persistence was calculated in months and analysed with a Kaplan-Meier estimate.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    Among women receiving teriparatide, age at menopause was lower in adherent than non-adherent patients (46.1 versus 50.0).

    In plain wordsAmong women receiving teriparatide, adherent patients had a lower age at menopause than non-adherent patients.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseAge at menopause by treatment adherence
    Study

    n = 50

    Comparator
    Non-adherent patients
    Outcome group
    Treatment adherence and retention · Whole body

    Measurements

    Age at menopause
    46.1 years
    adherent patients
    Age at menopause
    50 years
    non-adherent patients

    Source sentences

    Summary
    Apart from a significantly lower age at menopause in the adherent group (46.1 vs. 50.0; p < 0.006) there were no significant differences in baseline demographics between adherent and non-adherent patients.
    1 context sentence
    Summary · context
    A sample of 50 women with severe postmenopausal osteoporosis treated with TPTD in accordance to the German osteoporosis guidelines was included.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.